Karine Monique Hollis-Perry, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

Uniformed Services University Of The Health Sciences F. Edward Hébert School Of Medicine - Bethesda MD
Rank: Assistant Professor
Years: 2022-2023

None Reported

A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults
PLoS One
16(9):e0256980
Date: 09 2021
. doi: 10.1371/journal.pone.0256980

Pre-vaccination antibody titers against seasonal coronaviruses and antibody responses to the Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine in Healthcare Workers
Open Forum Infect Dis
Volume 8, Issue Supplement_1
Date: 11 2021
doi.org/10.1093/ofid/ofab466.642

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster
bioRxiv
2021.12.22.473880
Date: 12 2021
doi: 10.1101/2021.12.22.473880

Prospective Assessment of Symptoms to Evaluate Asymptomatic SARS-CoV-2 Infections in a Cohort of Health Care Workers
Open Forum Infect Dis
Volume: 9(3)
Date: 03 2022
doi: 10.1093/ofid/ofac030

Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers
Emerging infectious diseases
Volume: 28(4)
Date: 04 2022

SARS-CoV-2 BA1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies
Sci Transl Med
14(645)eabn8543
Date: 05 2022
doi: 10.1126/scitranslmed.abn8543

Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection
PLoS One
17(10):e0276241
Date: 10 2022
doi: 10.1371/journal.pone.0276241

Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history
Cell Host Microbe
Volume: 30(12)
Date: 12 2022
doi:10.1016/j.chom.2022.10.012

Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability
Front Immunol
14:1225025
Date: 08 2023
doi: 10.3389/fimmu.2023.1225025

Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers
Open Forum Infect Dis
9(1);ofab575
Date: 01 2024
doi: 10.1093/ofid/ofab575